Related Experiment Video
Updated: May 13, 2026

Acquisition of Resting-State Functional Magnetic Resonance Imaging Data in the Rat
Published on: August 28, 2021
Intranasal atomized dexmedetomidine for sedation during third molar extraction
N Nooh1, S A Sheta, W A Abdullah
1Department of Oral and Maxillofacial Surgery, King Saudi University, Riyadh, Saudi Arabia. nassernoohomfs@gmail.com
Intranasal dexmedetomidine effectively sedated patients undergoing third molar extraction. This method proved safe and convenient, offering a viable alternative for dental sedation.
Area of Science:
- Anesthesiology
- Pharmacology
Background:
- Sedation is crucial for managing patient anxiety and comfort during dental procedures.
- Mandibular third molar removal often requires effective sedation techniques.
Purpose of the Study:
- To assess the efficacy and safety of intranasal atomized dexmedetomidine for sedation during mandibular third molar extraction.
Main Methods:
- A randomized, crossover study involving 18 patients undergoing third molar removal.
- Patients received either intranasal dexmedetomidine (1.5 μg/kg) or placebo (water) in two sessions.
- Sedation levels were monitored using the Observer's Assessment of Alertness/Sedation (OAA/S) scale and bispectral index (BIS).
Main Results:
- Intranasal dexmedetomidine significantly improved sedation compared to placebo starting at 20-30 minutes post-administration.
- Peak sedation effects were observed between 40-50 minutes.
- Minor decreases in heart rate and blood pressure were noted, remaining within safe limits (<20% of baseline).
Conclusions:
- Intranasal atomized dexmedetomidine is an effective, safe, and convenient sedative for mandibular third molar extraction.
- This administration route offers a promising alternative for procedural sedation in dentistry.
Related Concept Videos
Parenteral Anesthetics: Overview
Skeletal Muscle Relaxants: Therapeutic Uses
Inhalational Anesthetics: Overview
Sedatives and Hypnotics Drugs: Miscellaneous Agents
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Stages of General Anesthesia
Depolarizing Blockers: Pharmocokinetics
